Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis

Published:2015-02-09 Issue:4 Volume:15 Page:465-475
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Abdel-Rahman Omar,Fouad Mona

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737140.2015.1014035

Reference30 articles.

1. Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

2. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

3. Erlotinib-Induced Skin Rash in Patients with Non–Small-Cell Lung Cancer: Pathogenesis, Clinical Significance, and Management

4. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury;Pharmacology & Therapeutics;2017-04

2. Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients;Expert Review of Clinical Pharmacology;2016-08-25

3. Chemotherapy (platinum and pemetrexed) in combination with erlotinib in non-small cell lung cancer induces major gastrointestinal toxicity: two case reports from the FLARE/GFPC 03-2013 study;Journal of Clinical Pharmacy and Therapeutics;2016-06-15

4. Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting;Future Oncology;2016-03

5. S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis;Future Oncology;2016-03